ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief medical officer.
Schneider has 16 years’ experience of clinical drug development and prior to her new role, she most recently served Allergan as its vice president and therapeutic head of retina and glaucoma.
Her new role will see her take responsibility for the development and execution of the company’s global clinical and medical programmes that are focused on its pipeline of drug candidates targeting diabetic eye disease.
Meanwhile, Vinciane Vangeersdaele has taken up the chief commercial officer position following 15 years of experience in a variety of sales and marketing leadership roles in the pharmaceutical industry, the latest being as the head of the ophthalmology franchise Europe at Novartis.
Vangeersdaele will be leading and developing the overall commercial strategy for the company’s recently formed Jetrea business unit, which was created following ThromboGenics regaining full rights to Jetrea from Novartis.
She will also lead the strategic marketing activities for any new compound that emerges from the company’s clinical development pipeline, which is focused on diabetic eye disease.
Patrik De Haes, chief executive officer, ThromboGenics, said: “We are very pleased to welcome Susan and Vinciane to the company.
“I am convinced that their extensive experience will be crucial as we simultaneously progress our pipeline of novel drug candidates targeting diabetic eye disease and develop our commercial plans for Jetrea beyond the US following our recent agreement with Novartis.”